The expectation of better future earnings growth due to the success of some of its relatively new drugs primarily drove Amgen’s valuation multiple higher. Our dashboard, ’ Why Amgen’s Stock Price Has Gained 50% Since 2017 Despite Revenues Growing A Mere 3%? ’ has the underlying numbers. What Brought About A Change In Earnings And Multiple?
Full Answer
What is the price of Amgen stock?
One share of AMGN stock can currently be purchased for approximately $213.85. How much money does Amgen make? Amgen has a market capitalization of $120.45 billion and generates $25.42 billion in revenue each year. The medical research company earns $7.26 billion in net income (profit) each year or $9.71 on an earnings per share basis.
How many insiders own Amgen (AMGN)?
Only 0.36% of the stock of Amgen is held by insiders. 74.95% of the stock of Amgen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Earnings for Amgen are expected to grow by 6.95% in the coming year, from $16.83 to $18.00 per share.
Is Amgen a buy or sell for this signal?
The Amgen Inc. stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average.
Will Amgen be added to the Dow Jones industrial average?
Shares of Amgen ( NASDAQ:AMGN) were vaulting 5.9% higher as of 3:21 p.m. EDT on Tuesday. The nice jump came after the announcement that the stock would be added to the Dow Jones Industrial Average, replacing Pfizer .
See more
Is AMGN a good stock to buy?
Amgen has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 3 buy ratings, 10 hold ratings, and 1 sell rating.
Is Amgen undervalued?
Amgen Is Undervalued By At Least 20%
Does AMGN pay a dividend?
THOUSAND OAKS, Calif. , Dec. 3, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.94 per share dividend for the first quarter of 2022. The dividend will be paid on March 8, 2022 , to all stockholders of record as of the close of business on February 15, 2022 .
How many outstanding shares does Amgen have?
534.2MShare StatisticsAvg Vol (3 month) 33.11MShares Outstanding 5534.2MImplied Shares Outstanding 6N/AFloat 8533.12M% Held by Insiders 10.22%7 more rows
Is Amgen growing?
Amgen is projecting compound annual growth in mid-single digits through the end of this decade. Considering the company reported 2021 revenue at $26 billion, that level of growth would get Amgen to roughly $35 billion in revenue in 2030.
Why is Amgen so successful?
Amgen's superior profitability gives it more flexibility compared to its peers if prices decrease further. The company can afford to lower its prices by a greater amount in order to maintain market share, as evidenced by its move with Repatha.
What months does AMGN pay dividends?
AMGN Dividend HistoryEx/EFF DATETYPEPAYMENT DATE02/13/2020CASH03/06/202011/14/2019CASH12/06/201908/14/2019CASH09/06/201905/16/2019CASH06/07/201940 more rows
How often does Amgen pay dividends?
There are typically 4 dividends per year (excluding specials), and the dividend cover is approximately 4.7. Our premium tools have predicted AMGEN Inc. with 99% accuracy.
How long has Amgen been paying a dividend?
10 yearsYes, AMGN's dividend has been stable for the last 10 years. Does Amgen have sufficient earnings to cover their dividend? Yes, AMGN's past year earnings per share was $10.18, and their annual dividend per share is $7.40.
Why did Amgen stock fall?
Revenue from its biggest moneymaker, inflammation treatment Enbrel, fell 7% to $843 million. Amgen also noted lower sales of Otezla, another inflammation drug, one it acquired from Bristol Myers Squibb (BMY). Otezla sales fell 5% to $350 million.
What sector is AMGN in?
Health CareKey DataLabelValueSectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations1 Year Target$250.00Today's High/Low$246.74/$242.3414 more rows
When did Amgen go public?
June 17, 19831983. Led by CFO Gordon Binder, Amgen's IPO on June 17, 1983, raises nearly $40 million.
How much does Amgen make?
Amgen has a market capitalization of $140.58 billion and generates $25.42 billion in revenue each year. The medical research company earns $7.26 billion in net income (profit) each year or $16.60 on an earnings per share basis.
What is the dividend payout ratio of Amgen?
Amgen does not yet have a strong track record of dividend growth. The dividend payout ratio of Amgen is 42.41%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Amgen will have a dividend payout ratio of 39.09% next year.
When is Amgen earnings call?
How can I listen to Amgen's earnings call? Amgen will be holding an earnings conference call on Tuesday, August 3rd at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "1682169".
How much did Amgen lose in the quarter?
For the quarter, Amgen's revenue fell 4% year over year to $5.9 billion. This was due to a drop in overall selling prices for the company's products, offset somewhat by increased volume. As for adjusted net profit, it was $2.15 billion ($3.70 per share), representing a steeper fall of 14%.
How much is Amgen's EPS for 2021?
Amgen reiterated its full-year 2021 forecasts for revenue and adjusted EPS. The former stays at $25.8 billion to $26.6 billion, and the latter is $16 to $17.
How much did Amgen stock gain in 2021?
The Amgen Inc. stock price gained 0.38% on the last trading day (Friday, 9th Jul 2021), rising from $244.28 to $245.20. , and has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the day the stock fluctuated 1.75% from a day low at $241.71 to a day high of $245.93. The price has risen in 7 of the last 10 days and is up by 1.76% over the past 2 weeks. Volume fell on the last day by -368 thousand shares and in total, 2 million shares were bought and sold for approximately $392.56 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.
Does Amgen stock have a buy signal?
The Amgen Inc. stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average.
What happened
Shares of Amgen ( AMGN -0.41% ) were vaulting 5.9% higher as of 3:21 p.m. EDT on Tuesday. The nice jump came after the announcement that the stock would be added to the Dow Jones Industrial Average, replacing Pfizer .
So what
There are two main reasons why investors cheered today's news for Amgen. One was more symbolic, while the other was quite practical.
Now what
Amgen won't officially become part of the Dow Jones index until Aug. 31, 2020. While the stock's addition to the index will provide a temporary boost, the more important thing to focus on will continue to be Amgen's pipeline progress.
When is Amgen's 2021 conference?
Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 42nd Annual Global Healthcare Conference at 4:40 p.m. ET on Wednesday, June 9, 2021. David M. Reese, M.D., executive vice president of Research and Development and Peter H. Griffith, executive vice president and chief financial officer at Amgen will present at the conference. Live audio of the conference call will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public
What does the FDA approval of Biogen Alzheimer's mean?
Julie Hyman and Anjalee Khemlani breakdown what the FDA’s approval of Biogen’s Alzheimer’s drug will mean for the pharmaceutical industry as Biogen experienced a surge in shares and releases the cost of the treatment.
Is Amgen approved in Japan?
Amgen (NASDAQ:AMGN) today announced that the Japanese Ministry of Health, Labour and Welfare has granted marketing approval for Aimovig® (erenumab) for the suppression of onset of migraine attacks in adults. Aimovig is the first and only approved treatment in Japan to block the calcitonin gene-related peptide receptor (CGRP-R), which is believed to play a critical role in migraine.3 This is also the first independent submission and approval for Amgen K.K., a wholly owned affiliate of Amgen Inc.
Sales
Risks
- 17 Wall Street analysts have issued 12 month price objectives for Amgen's stock. Their forecasts range from $179.00 to $232.00. On average, they anticipate Amgen's share price to reach $207.4706 in the next year. This suggests a possible upside of 20.7% from the stock's current price. View Analyst Price Targets for Amgen.
Ratings
- 17 Wall Street analysts have issued \"buy,\" \"hold,\" and \"sell\" ratings for Amgen in the last year. There are currently 9 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of \"Hold.\" View Analyst Ratings for Amgen.
Reception
- Media stories about AMGN stock have trended somewhat positive on Sunday, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most f…
Ownership
- Amgen's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.56%), Wells Fargo & Company MN (1.23%), LSV Asset Management (0.64%), Sumitomo Mitsui Trust Holdings Inc. (0.41%), Dimensional Fund Advisors LP (0.39%) and Parametric Portfolio Associates LLC (0.38%). Company insiders that own Amge…
Business
- Amgen has a market capitalization of $104.82 billion and generates $23.75 billion in revenue each year. The medical research company earns $8.39 billion in net income (profit) each year or $14.40 on an earnings per share basis. Amgen employs 21,500 workers across the globe.
Infrastructure
- Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected].